Alkem Laboratories Reports 17% Revenue Growth, 22% EBITDA Growth in Q2 FY26
Alkem Laboratories announced strong Q2 FY26 results with 17% revenue growth and 22% EBITDA growth. The company saw growth in India, US and international markets.
The strong financial results, especially the significant growth in revenue and EBITDA, along with the expansion in key markets, suggest a high positive impact on the company's prospects and investor confidence.
The announcement highlights strong financial performance, including significant revenue and EBITDA growth, along with positive comments from the CEO, indicating a positive outlook for the company.
* Alkem Laboratories Ltd. announced its Q2 & H1FY26 financial results, with the Board of Directors taking record of these results at its meeting held in Mumbai on November 13, 2025. * Total Revenue from Operations was ₹ 40,010 million, with YoY growth of 17.2%. * India sales were ₹ 27,660 million, YoY growth of 12.4%. * International sales were ₹ 11,890 million, with YoY growth of 29.5%. * US sales were ₹ 7,649 million, YoY growth of 28.0%. * Non-US sales were ₹ 4,241 million, YoY growth of 32.4%. * EBITDA was ₹ 9,208 million, resulting in an EBITDA margin of 23.0%. * R&D expenses for Q2 FY26 were ₹ 1,302 million, or 3.3% of total revenue. * Profit before tax was ₹ 8,958 million, YoY growth of 14.8%. * Net Profit was ₹ 7,651 million, YoY growth of 11.1%. * During Q2 FY26, the Company filed 02 ANDAs, received 01 ANDA tentative approvals and launched 04 products for the US market. * CEO Dr. Vikas Gupta commented that Q2 FY26 was a strong quarter with robust growth across India, the US, and key international markets. He also mentioned healthy traction in new product launches and a focus on accelerating growth and strengthening presence in key markets.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.